16 July 2025 - Genascence Corporation today announced that the US FDA has granted the regenerative medicine advanced therapy designation to GNSC-001, a potential first in class gene therapy blocking interleukin-1 for the treatment of knee osteoarthritis.

GNSC-001 is a genetic medicine – a recombinant adenovirus associated viral vector expressing an optimised human interleukin-1 receptor antagonist, a naturally occurring protein that blocks interleukin-1 signalling.

Read Genascence press release